It might play a role as a biomarker to monitor therapy response to PKC412, which was recently approved for the treatment of FLT3‐mutated AML, and might be of potential interest as a treatment target for future therapies overcoming drug resistance. Here, FLT3 is linked to acute myeloid leukemia.